Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-400 in metastatic colorectal cancer
NCT06107413Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 8
01
Overview
A Phase 2 trial of telisotuzumab adizutecan in metastatic colorectal cancer (mCRC), sponsored by AbbVie Inc.. Started Nov 2023; status: active, not recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06107413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107413.